Last reviewed · How we verify
Convalescent anti-SARS-CoV-2 MBT plasma
Convalescent anti-SARS-CoV-2 MBT plasma is a Biologic drug developed by Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia. It is currently in Phase 2 development for Treatment of COVID-19.
Convalescent anti-SARS-CoV-2 MBT plasma is a treatment that uses antibodies from recovered COVID-19 patients to help the body fight the virus.
Convalescent anti-SARS-CoV-2 MBT plasma is a treatment that uses antibodies from recovered COVID-19 patients to help the body fight the virus. Used for Treatment of COVID-19.
At a glance
| Generic name | Convalescent anti-SARS-CoV-2 MBT plasma |
|---|---|
| Sponsor | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
This treatment involves the administration of antibodies that have been shown to be effective against SARS-CoV-2, which can help to neutralize the virus and reduce the severity of symptoms. The antibodies are derived from the plasma of recovered patients, which contains a high concentration of these beneficial antibodies.
Approved indications
- Treatment of COVID-19
Common side effects
- Injection site reactions
- Fever
- Headache
Key clinical trials
- Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients (PHASE2)
- A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Convalescent anti-SARS-CoV-2 MBT plasma CI brief — competitive landscape report
- Convalescent anti-SARS-CoV-2 MBT plasma updates RSS · CI watch RSS
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia portfolio CI
Frequently asked questions about Convalescent anti-SARS-CoV-2 MBT plasma
What is Convalescent anti-SARS-CoV-2 MBT plasma?
How does Convalescent anti-SARS-CoV-2 MBT plasma work?
What is Convalescent anti-SARS-CoV-2 MBT plasma used for?
Who makes Convalescent anti-SARS-CoV-2 MBT plasma?
What development phase is Convalescent anti-SARS-CoV-2 MBT plasma in?
What are the side effects of Convalescent anti-SARS-CoV-2 MBT plasma?
Related
- Manufacturer: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of COVID-19
- Compare: Convalescent anti-SARS-CoV-2 MBT plasma vs similar drugs
- Pricing: Convalescent anti-SARS-CoV-2 MBT plasma cost, discount & access